AMS Reports FY2025 Results, Strong Surgical Growth

Advanced Medical Solutions Aligns with Market Expectations

Advanced Medical Solutions Group (LSE:AMS) announced its fiscal year 2025 results, which met both its January trading statement and analyst consensus. The company reported revenues of £228.9 million and an adjusted EBITDA of £49.9 million, achieving a margin of 21.8%.

Divisional Performance Overview

The company's growth was primarily driven by its Surgical Care division, which recorded a substantial 36% increase on a constant currency basis. Within this division, the ex-Peters segment grew approximately 11%, supported by double-digit growth across most product categories.

The Wound Care division also saw positive results, with revenue increasing by 9% on a constant currency basis. This growth reflects strong performance in customer-branded and bulk materials. Divisional margins were reported at 24.4% for Surgical and 13.6% for Wound Care. However, group earnings per share was 3% below FactSet consensus due to higher interest expenses.

Future Outlook and Synergies

Looking ahead to fiscal year 2026, Advanced Medical Solutions expressed confidence in meeting current market expectations, which project £244.6 million in revenue and £40.6 million in adjusted profit before tax. The company anticipates continued strong growth in its Surgical division and modest growth in Woundcare.

Operational synergies from the acquisitions of Peters in July 2024 and Syntacoll in March 2024 are progressing as planned. The company also confirmed that commercial synergies are already contributing to its growth trajectory. Strong cash generation is expected to support deleveraging while funding innovation and manufacturing optimization.

Summary

Advanced Medical Solutions has delivered a solid financial performance, aligning with market expectations and demonstrating robust growth, particularly in its Surgical division. The company's outlook for fiscal year 2026 remains positive, supported by successful acquisition integrations and a focus on disciplined capital allocation.

FAQ

Q: What were AMS's key financial results for fiscal year 2025?

A: AMS reported revenues of £228.9 million and adjusted EBITDA of £49.9 million, consistent with prior guidance.

Q: Which business division showed the strongest growth?

A: The Surgical Care division led with 36% growth on a constant currency basis.

Q: What is the company's outlook for fiscal year 2026?

A: AMS is confident in delivering revenue and EBITDA in line with current market expectations, which stand at £244.6 million in revenue.

Source: Investing.com